

# Index

- A**
- Actin
- filament action in nucleus
    - assembly, 159–161
    - cell cycle, 162–163
    - DNA damage repair, 163–164
    - long-range chromatin motion, 162
    - signaling, 161–162
    - viral replication, 163
  - monomer action in nucleus
    - allosteric regulation of chromatin remodeling complexes, 157–158
    - MRTF/SRF-mediated transcription signaling, 155, 157
    - pools in cytoplasm and nucleus, 154–155
    - RNA polymerase II functions, 158–159
    - signaling functions, 156
  - overview, 153–154
- Activin A, 493
- ACTN4, 163
- AKT, 78
- ALPS domains, 31
- Alternative polyadenylation (APA), 358
- AMPK, 99
- ANCHOR, 313
- AP-1, 389, 396
- AP-2, 389
- APA. *See* Alternative polyadenylation
- APEX, 284
- AR, 373, 379
- ARID1A, 158
- Arp2/3, 159, 161, 163–164
- ASAR, 341–342
- ATAD2, 498
- ATG11, 35
- ATG8, 35
- ATRX, 399
- B**
- BAF, 6–7, 74, 78, 157–158, 372–373, 377, 381, 492, 498
- BANF1, 17
- Barr body, 269
- BCR-ABL fusion, 375
- BDNF, 358
- BMAL1, 77
- BPTF, 492
- BRD4, 114, 315, 381, 392, 503
- Btf, 74
- C**
- CAF-1, 435
- Cajal body, 257, 273–274
- Calcium flux, mechanotransduction, 98
- Cancer
- chromatin machinery defects
    - cis*-regulatory elements
      - aneuploidy, gene expression, and nuclear structure, 379–381
      - enhancer amplification, 378–379
      - enhancer hijacking, 378
      - oncogenes, 379
      - transcription factor binding, 377–378
    - deletions
      - RB1, 377
      - SMARCB1, 377
    - large-scale alterations, 375–376
    - mutations
      - chromatin remodeling complexes, 373
      - DNA methylation genes, 373–374
      - histone modifiers, 374–375
      - histones, 372
      - transcription factors, 372–373
    - MYC/MYCN gene amplifications, 376–377
    - overview of machinery, 371–372, 381
    - prospects for study, 381–382
    - overview of genetic errors, 369–371
- Cbfl, 54
- CBP, 238, 276, 374, 395
- CCM. *See* Chromosome copolymer model
- CD47, 358
- CDK, 337, 339
- CDK1, 3, 32
- CDK5, 3
- CDK9, 115, 118, 397
- CEC-4, 14
- CELF1, 460, 469, 475
- CENP-A, 162
- CENP-C, 500
- CFP1, 431

## Index

- CHD1, 373, 498  
CHM7, 34, 78  
Chromatin. *See also* Nucleosome  
cancer defects. *See* Cancer  
deformation by force, 97  
folding in embryogenesis. *See* Embryogenesis  
lamina-associated domain geographic organization, 12  
mechanical properties and genome organization/function, 99–101  
motion  
constraints, 177–181  
overview, 176–179  
organization in nucleus, 175–176  
pluripotent cell structure  
chromosome organization, 500  
loops, domains, and interaction hubs, 500–502  
nucleosome organization, 496  
open chromatin  
genome accessibility, 498  
remodeling, 498–499  
overview, 494–496  
prospects for study, 502–503  
prospects for study, 181–182  
RNA interactions. *See* RNA–chromatin interactions structure  
fibers and condensates in vitro, 174–175  
overview, 169–171, 173  
three-dimensional modeling of genome folding approaches, 211–213  
data-driven modeling  
data deconvolution, 219–221  
resample methods, 221–222  
mechanistic modeling  
chromatin loops and topologically associating domains, 214–215  
combining loop extrusion and block copolymer models, 216–219  
global chromatin compartmentalization, 215–216  
overview, 209–211  
prospects for study, 222–223  
Chromatin subcompartment (CSC)  
assembly studies, 116  
chromocenter  
features as phase-separated subcompartment, 114  
high-resolution structure, 115, 117  
liquid–liquid phase separation contribution to structure, 122–123  
marker protein internal mixing and nucleoplasm exchange, 118  
structure–function relationships in establishment, 121–122  
formation mechanisms, 110–112  
nucleic acid/protein ratios and local viscosity, 118–119  
nucleolus  
features as phase-separated subcompartment, 113  
high-resolution structure, 115  
liquid–liquid phase separation contribution to structure, 122–123  
marker protein internal mixing and nucleoplasm exchange, 117  
structure–function relationships in establishment, 119–120  
overview, 109–110, 285–288  
prospects for study, 123–124  
RNA polymerase II transcription factories  
features as phase-separated subcompartment, 113–114  
high-resolution structure, 115  
liquid–liquid phase separation contribution to structure, 122–123  
marker protein internal mixing and nucleoplasm exchange, 117–118  
structure–function relationships in establishment, 120–121  
Chromocenter. *See* Chromatin subcompartment  
Chromosome copolymer model (CCM), 218  
Chromosome folding  
cell cycle changes in chromosome shape, 200–201  
cell-type specificity and nuclear organization, 201–202  
compartmentalization, 191–193  
interplay between mechanisms  
compartmentalization versus tethering, 199  
extrusion versus compartmentalization, 198–199  
transcription, compartmentalization, and loop extruders, 199–200  
loop extrusion  
functional roles, 195–196  
mechanics, 194–196  
overview, 193–194  
mechanisms, 189–191  
pluripotent cells. *See* Pluripotency  
tethering to subnuclear structures, 196–198  
three-dimensional modeling of loop extrusion, 214–219  
topological effects, 198

- Cis*-regulatory elements (CREs)  
cancer alterations  
aneuploidy, gene expression, and nuclear structure, 379–381  
enhancer amplification, 378–379  
enhancer hijacking, 378  
oncogenes, 379  
transcription factor binding, 377–378  
hubs, 309–311  
kinetics, 312–313  
overview, 303–304  
spatial scales in nucleus, 305  
transcription-associated nuclear foci, 311
- CIZ1, 460  
Cleavage body, 276–277  
Clk1, 292  
CMV. *See* Cytomegalovirus  
Cofilin, 154  
Cohesin, 51, 307–309  
Coilin, 273  
Condensin II, 200  
Constant timing region (CTR), 328, 330  
CREs. *See* *Cis*-regulatory elements  
CRM1, 33–34  
CSC. *See* Chromatin subcompartment  
CTCF, 10–11, 51–52, 118, 135–136, 142–143, 145, 175, 193–196, 200–202, 214–216, 219, 221, 235, 306–309, 315, 333, 335, 338, 372–374, 381, 395–396, 410, 412, 415–416, 419–420, 437–438, 440, 466, 469–470, 500  
CTR. *See* Constant timing region  
Cytomegalovirus (CMV), 163, 399–400
- D**  
DAXX, 276  
DDK, 337, 339  
Development. *See* Embryogenesis  
DNA-FISH, 306–307, 317  
DNA methylation. *See* Epigenetics  
DNA polymerase, 339  
DNA replication timing  
cytological studies, 330–332  
genome-wide profiling, 328  
Hi-C compartment correlation, 332–333  
overview, 327–328  
prospects for study, 342–343  
regulation  
early replication control elements, 338–339  
initiation, 337–338  
*trans*-acting regulators, 339–341  
whole chromosome territory regulation, 341–342  
single-cell measurements, 328, 330  
subnuclear landmarks  
lamina-associated domains, 335–336  
models of nuclear organization, 337  
nucleolus-associated domains, 335–336  
speckle-associated domains, 336–337  
topologically associating domains and replication domain relationship, 333, 335  
DNMT1, 377, 429–430  
DNMT3A, 429  
DNMT3B, 429  
DNMT3C, 429  
DNMT3L, 429  
DPPA2, 433, 436  
DPPA4, 433, 436  
DUX, 436  
DYT1, 79
- E**  
Eaf1, 158  
Early replication control element (ERCE), 338–339, 342–343  
EBNA1, 394  
EBNA2, 394  
EBNA3C, 394  
EBNA-LP, 394  
EBV. *See* Epstein–Barr virus  
EED, 433  
Embryogenesis  
chromatin folding and gene expression  
CTCF in domain insulation, 415  
dynamic versus preformed folding, 413–415  
structural variation impact on genome organization, 417–419  
topologically associating domains in gene expression, 415–416  
transcriptional control mechanisms, 416–417  
transposable element functions, 419–420  
genome three-dimensional organization  
early embryogenesis, 412–413  
overview, 410–412  
prospects for study, 420–421  
X chromosome inactivation. *See* X chromosome inactivation  
Embryonic stem cell (ESC), 490–491, 494, 498, 502  
Emerin, 6, 16, 60, 75–76, 274  
ENCODE project, 305, 498  
Enhancer  
*cis*-regulatory elements and cancer alterations  
amplification, 378–379  
hijacking, 378  
enhancer–promoter proximity  
bursting in single-cell studies, 145–147

## Index

### Enhancer (*Continued*)

- range of action, 144–145
- transcription activation dependence, 143–144
- EP300, 381
- EPHA4, 219, 417
- Epigenetics
  - histone modifier defects in cancer, 374–375
  - nuclear pore complex in memory regulation, 54–55
- pluripotency
  - DNA methylation, 492
  - histone modification, 492–493
- reprogramming in early development
  - DNA methylation, 429–430
  - histone modification
    - bivalent modifications, 433
    - H2K119ub, 434
    - H3K27me3, 431–433
    - H3K36me2/3, 434–435
    - H3K4me3, 430–431
    - H3K9me3, 435–436
  - overview, 427–429
  - preimplantation embryo chromatin maturation, 440
  - prospects for study, 440–445
  - transposable elements, 436
- Epstein–Barr virus (EBV), 390, 393–394
- ER, 114, 118
- ERCE. *See* Early replication control element
- ERVK, 435
- ERVL, 435
- ESC. *See* Embryonic stem cell
- ESCRT-III, 77–78, 80
- ETS2, 373
- EWS, 375
- EZH2, 374

### F

- FAM208A, 397
- FAN-1, 73
- FBL. *See* Fibrillarin
- Fertilization, conserved relaxed chromatin organization, 438–440
- FGF2, 493
- FGF4, 374
- Fibrillarin (FBL), 113, 115, 117, 119
- 53BP1, 73
- FIRRE, 263
- FLASH, 262, 276
- FLI1, 375
- FOXA1, 118
- FOXO1, 375–376, 378

### G

- GAGA, 53
- GAL1, 53
- GAL4, 235
- GAM. *See* Genome architecture mapping
- GATA2, 144
- GATA3, 378
- GATOR2, 37
- GCL, 74
- GCN4, 114
- Gcn4, 53
- Genome architecture mapping (GAM), 285, 309
- Genome structure
  - enhancer-dependent transcription activation, 143–144
  - enhancer–promoter proximity
    - bursting in single-cell studies, 145–147
    - range of action, 144–145
  - ensemble studies, 135–137
  - ensemble topologically associating domains, 142–143
  - single-cell studies, 137–139
  - techniques for study, 134
  - topologically associating domains, 142–143
  - transcription and stochastic genomic structure, 139–142, 147
- GFII, 378, 417
- GFI1B, 378, 417
- GLI1, 75
- GRS1, 54
- GRS2, 54
- GSK3, 492

### H

- H1, 171, 181, 371
- H19, 252
- H2A, 171, 371
- H2B, 171, 371
- H3, 171, 181, 201, 371–372
- H4, 171, 371
- HAND2, 381
- HBV. *See* Hepatitis B virus
- HDAC3, 14, 74–75, 258, 470, 474
- Heh1, 78
- Hepatitis B virus (HBV), 390, 395, 400
- HERV-H, 420
- HHV-6B, 399
- Hi-C, 134–138, 191–195, 198–199, 213–222, 282–285, 332–334, 380–381, 393–395, 409–412, 490, 500–501
- HIRA, 276
- Histone locus body (HLB), 257, 276
- Histone modification. *See* Epigenetics

- HIV. *See* Human immunodeficiency virus
- HLB. *See* Histone locus body
- HMGB1, 395
- HOXA9, 55
- HOXD13, 55
- HP1, 12, 65, 110, 114–115, 118, 121–123, 181, 216, 241, 260, 287, 416, 497
- HPV. *See* Human papillomavirus
- HSP70, 357
- HSPA1A, 290–291
- HSPA1B, 290
- HSV-1, 390–391
- HSV-2, 390–391
- HTLV-1, 390, 395
- Human immunodeficiency virus (HIV), 74, 390–393, 396–397, 399–400
- Human papillomavirus (HPV), 390, 399
- HUSH, 396–397
- I**
- ICM. *See* Inner cell mass
- ICP0, 399
- IDH1, 373
- IDH2, 373
- IDRs. *See* Intrinsically disordered regions
- IE1, 399
- IGF2, 417
- IGM. *See* Integrated Genome Modeling
- Importin  $\beta$ , 32, 34
- INF2, 162
- INM. *See* Inner nuclear membrane
- Inner cell mass (ICM), 490
- Inner nuclear membrane (INM)  
overview, 59–64  
proteins. *See also specific proteins*  
diseases, 68–71  
emerin, 75–76  
LAP1, 79–80  
LAP2, 74–75  
LBR, 65, 67, 72  
LEM domain proteins, 74  
LEM2, 77–79  
MAN1, 76–77  
SAMP1, 79  
SUN domain proteins, 72–74  
table, 61–63  
proteomes, 8
- INO1, 54
- INO80, 158, 162, 373
- Integrated Genome Modeling (IGM), 220
- Intrinsically disordered regions (IDRs), transcription factor dynamics  
evolution, 240  
overview, 237–238  
phase separation driving, 238–239  
sequence determination of transcription factor interactions, 239–240  
stoichiometric complexes, 238  
target search facilitation, 239
- ISWI, 373
- K**
- KAP1, 436, 492
- Kaposi's sarcoma–associated herpesvirus (KSHV), 390
- KASH domain, 7, 72, 274
- KASH5, 72
- KAT14, 158
- KCNJ12, 415–417
- KDM proteins, 374–375
- KDMA4, 435
- KIT, 374
- KLF4, 492, 498, 500
- KLF5, 379
- KMT2B. *See* MLL2
- KMT5C, 118, 122
- KSHV. *See* Kaposi's sarcoma–associated herpesvirus
- Ku80, 164
- L**
- LADs. *See* Lamina-associated domains
- Lamina  
laminopathies, 15–17  
lamins. *See also specific lamins*  
classification, 1–3  
lamina interface scaffolding, 6–8  
regulation, 3–5  
overview, 1–3, 274  
prospects for study, 17  
proteomes, 8–9
- Lamina-associated domains (LADs)  
binary compartment model, 282–283  
cell cycle and dynamic organization, 15  
DNA replication timing, 335–336  
gene regulation, 12–13  
geographic organization and chromatin state, 12  
localization, 292  
organization and expression programs, 14–15  
preimplantation embryo chromatin maturation, 440  
techniques for study, 8, 10–11  
transcription factors in organization, 13–14
- Laminin-111, 154
- LAP1, 79–80
- LAP2, 6, 8, 14, 60, 74–75, 274

## Index

- LBR, 6, 16, 60, 65, 67, 72, 197, 199, 274  
LEDGF, 397  
LEM2, 60, 77–79, 274  
LIE, 493  
LINC proteins, 6–7, 17, 95–97, 161  
LINE1, 436, 465  
LMNA, 1–3, 5, 15–17, 95, 274  
LMNAΔ10, 1–2  
LMNB1, 1–3, 5, 16, 67  
LMNB2, 1–3, 5  
LMNB3, 1–2  
LMNC, 1–3, 95  
LMNC2, 2–3  
LMO1, 145  
Loop extrusion. *See* Chromosome folding  
LULL1, 79–80
- M**
- MAJIN1, 72  
MALAT1, 284, 287  
MaLR, 435  
MAN1, 6, 16, 60, 74, 76–77, 274  
MARGI, 284  
MATR3, 460, 469, 475  
MAX, 376–377  
MCM, 335  
MDN1, 357–358  
Mechanical force. *See also* Mechanotransduction  
chromatin mechanical properties and genome organization/function, 99–101  
DNA damage, 101–103  
overview in cells and tissues, 93–94  
Mechanotransduction  
force-mediated regulation of transcription and cell state, 97–99  
nucleus mechanosensing  
chromatin deformation by force, 97  
cytoskeletal modulation, 97  
nuclear deformation sensing, 96  
nuclear transport and signaling regulation, 96–97  
overview, 94, 96  
principles, 95–96  
prospects for study, 103–104  
MeCP2, 65, 115, 118, 121–123  
MED1, 115, 121, 392, 503  
*Med14*, 476  
Mediator, 50, 309, 315, 352–353  
MEGABASE, 217  
MERV-L, 419, 436  
MET-2, 197  
Mex67, 50  
MFAP1, 287  
MICAL-2, 154  
MINA, 310  
MLL1, 55, 373  
MLL2, 373, 430, 433  
MLLT1, 374  
Mlp1, 51  
Mlp2, 51  
MLV. *See* Murine leukemia virus  
MOF, 464  
MOZ, 373  
MPP8, 397  
Mps3, 73  
Mre11, 164  
MRTF, 95  
MRTF/SRF-mediated transcription, actin signaling, 155, 157  
MRTF-A, 155, 157  
*MUC4*, 115  
Murine leukemia virus (MLV), 390, 396–397  
MVM, 393  
MX2, 391  
MYC, 376–379, 393, 492  
MYCN, 376–377  
MYOD, 381  
MYOD1, 373
- N**
- NADs. *See* Nucleolus-associated domains  
NANOG, 464–465, 492–493, 498, 500, 503  
NCL. *See* Nucleolin  
NDP52, 159  
NEAT1\_2, 275, 287  
NEK, 32  
Nesprin1, 16  
Nesprin2, 16  
NET5, 60  
Neural stem cell (NSC), 501  
NIK, 161  
NM1, 159  
Noncoding RNA. *See* RNA–chromatin interactions  
NONO, 275  
NP220, 396  
NPAT, 262, 276  
NPC. *See* Nuclear pore complex  
NPM1, 114–115, 117, 119  
NR4A3, 378  
NRF2, 400  
NS1, 395, 400  
NSC. *See* Neural stem cell  
NSD1, 430, 434  
Nsd1, 55  
NTC, 355–356  
NuA4, 157–158

- Nuclear compartments. *See also* Chromatin subcompartment; *specific compartments*
- Cajal body, 273–274
- cleavage bodies, 276–277
- establishment and maintenance, 288–289
- functions, 289
- genomic analysis of genome nuclear organization, 282–285
- histone locus body, 276
- imaging
- early cytology, 277–278
  - genomics combination studies, 285
  - radial and binary models of nuclear compartmentalization, 278–279, 281–282
- lamina, 274–275
- liquid–liquid phase separation, 285–288
- nuclear pore, 274–275
- nuclear speckles, 272–273, 290–292
- nucleolus, 270, 272
- paraspeckles, 275–276
- perinucleolar compartment, 276
- promyelocytic leukemia body, 276
- prospects for study, 292–293
- virus interactions
- nuclear speckles, 400–401
  - promyelocytic leukemia body, 397–400
- Nuclear pore complex (NPC)
- composition, 29
  - functions, 36–37
  - life cycle in dividing cells, 32–34
  - maintenance and turnover, 34–36
  - overview, 27–28, 274–275
  - prospects for study, 37
  - RNA export competence and ribonucleoprotein identity, 359
  - structure, 28–32
  - transcriptional regulation
    - epigenetic memory regulation, 54–55
    - gene silencing, 51
    - mechanisms of gene interactions, 50–51
    - overview, 49–50
    - transcriptional regulation, 51–54  - virus entry, 390–393
- Nuclear speckles, 255, 257, 272–273, 290–292, 400–401
- Nucleolin (NCL), 113, 115, 117, 119
- Nucleolus
- chromatin subcompartment
    - features as phase-separated subcompartment, 113
    - high-resolution structure, 115
    - liquid–liquid phase separation contribution to structure, 122–123
    - marker protein internal mixing and nucleoplasm exchange, 117
    - structure–function relationships in establishment, 119–120
    - history of study, 251
    - overview, 270, 272
    - RNA processing, 254–255
- Nucleolus-associated domains (NADs), DNA replication timing, 335–336
- Nucleosome
- interactions in chromatin motion restriction, 180
  - pluripotent cell organization, 496
  - structure, 171–172
- Nup1, 54
- Nup2, 50
- Nup35, 32
- Nup50, 30
- Nup53, 32
- Nup54, 30
- Nup58, 30
- Nup60, 51
- Nup62, 30, 391
- Nup88, 30
- Nup93, 30, 33, 51
- Nup98, 30, 54–55
- Nup100, 54
- Nup107, 30, 33–34, 51
- Nup145, 51
- Nup153, 30, 34, 391
- Nup155, 30–32
- Nup157, 31
- Nup159, 35
- Nup160, 30, 33–34, 51
- Nup170, 31, 51
- Nup188, 31
- Nup192, 31
- Nup205, 30–31, 33
- Nup210, 53
- Nup214, 30, 391
- Nup358, 30–31, 391
- O**
- OCT4, 114, 464–465, 492–493, 498, 500, 503
- Oct4, 98, 160
- Oogenesis, genome organization, 438
- P**
- p53, 159, 291, 373
- p300, 374, 395
- Paraspeckles, 275–276

## Index

- PARP, 241  
PAX3, 375–376, 378, 417  
PAX5, 381  
PAX8, 378  
PBAF, 377  
PCAF, 159  
PCGF3, 473  
PCGF5, 473  
PCNA, 163  
PDGFRA, 374  
Perinucleolar compartment (PNC), 276  
PGC. *See* Primordial germ cell  
Phase separation  
  liquid–liquid phase separation  
    chromocenter, 114, 122–123  
    intrinsically disordered region  
      driving, 238–239  
    nuclear compartments, 285–288  
    nuclear structure overview, 311–312  
    nucleolus, 113, 122–123  
    RNA polymerase II transcription factories,  
      113–114, 122–123  
  polymer–polymer phase separation, 312  
  *Xist* RNA compartment, 468–469  
PKC, 3  
PLK1, 32  
Pluripotency  
  chromatin structure  
    chromosome organization, 500  
    loops, domains, and interaction hubs,  
      500–502  
    nucleosome organization, 496  
    open chromatin  
      genome accessibility, 498  
      remodeling, 498–499  
    overview, 494–496  
    prospects for study, 502–503  
  continuum, 494  
  epigenetics  
    DNA methylation, 492  
    histone modification, 492–493  
  history of study, 490–491  
  overview, 489  
  regulatory networks, 491–492  
  states, 493–494  
PML, 398–400  
PML body. *See* Promyelocytic leukemia body  
PNB. *See* Prenucleolar body  
PNC. *See* Perinucleolar compartment  
Pom121, 31, 34  
Population-based genome structure modeling,  
  219–221  
PPHLN1, 397  
PRC1, 260, 433, 465, 468, 470–471, 473, 475  
PRC2, 372, 374, 431, 433, 465, 470–471, 475  
PRDM14, 464–465  
Prenucleolar body (PNB), 270, 272  
PREP1, 339  
Primordial germ cell (PGC), 490  
Promyelocytic leukemia (PML) body, 276,  
  397–400  
PRPF38A, 287  
PSE, 275  
PSPC1, 275  
PTBP1, 460, 469, 475  
P-TEFb, 396  
PTEN, 276  
Put3, 54  
  
**R**  
RAD21, 333, 335  
Rad51, 164  
RanGTP, 33–34  
RanGTPase, 154  
RASSF1A, 154  
RB1, 377  
RBM15, 471  
RCC1, 33  
Replication timing. *See* DNA replication timing  
REX1, 464–465  
RIF1, 341  
RING1B, 473  
RMB14, 275  
RNA polymerase I, chromatin motion restriction,  
  181  
RNA polymerase II, 73, 143–144, 229, 277, 285, 315,  
  355–358, 394–396, 467, 469  
  actin functions, 158–159  
  chromatin motion restriction, 180–181  
  RNA processing coupling, 359–360  
  transcription factor clustering, 241  
  transcription factory as chromatin  
    subcompartment  
      features as phase-separated subcompartment,  
        113–114  
      high-resolution structure, 115  
      liquid–liquid phase separation contribution  
        to structure, 122–123  
      marker protein internal mixing and  
        nucleoplasm exchange, 117–118  
      structure–function relationships in  
        establishment, 120–121  
  RNA–chromatin interactions  
    chromatin regulation and gene expression  
    functional roles of RNA-mediated nuclear  
      compartments, 260



- nuclear compartment organization by RNA, 258, 260
  - X chromosome inactivation, 258
  - global RNA disruption and morphological changes in nucleus, 253
  - history of study, 251–252
  - mechanisms of RNA-mediated nuclear organization
    - overview, 260–262
    - phase separation, 262–264
  - noncoding RNA in nuclear processes, 252–253
  - prospects for study, 264
  - RNA processing
    - Cajal body, 257
    - histone locus body, 257
    - nuclear bodies in promotion of cotranscriptional RNA processing, 257–258
    - nuclear speckles, 255, 257
    - nucleolus, 254–255
  - RNA splicing
    - overview, 355–356
    - RNA imaging techniques, 350–352
    - spliceosome assembly, 356
    - timing relative to transcription, 356–357
  - RNF12, 465
  - rRNA, 254–255
  - RSX, 462, 465
  - RYBP, 473
- S**
- SAF-A, 176, 258, 460
  - SAGA, 50
  - SAHF. *See* Senescence-associated heterochromatin foci
  - SAMP1, 79
  - SC35, 272, 400
  - scaRNA, 257
  - SCNT. *See* Somatic cell nuclear transfer
  - SCPP, 378
  - Sec13, 37, 53
  - Seh1, 37, 54
  - SELEX, 230
  - Senescence-associated heterochromatin foci (SAHF), 51
  - Set1, 159
  - SET-25, 197
  - SETD2, 429–430, 434, 475
  - SHARP, 258–260, 262–263
  - SHREC, 77
  - Sir2, 51
  - Sir3, 51
  - Sir4, 51
  - SMAD1, 76–77
  - SMAD2, 76
  - SMAD3, 76
  - SMAD5, 76–77
  - SMAD8, 77
  - SMARCA4, 381
  - SMARCB1, 377
  - SMCHD1, 469–470, 475
  - SMN, 273
  - snoRNA, 252
  - snRNA, 252–253, 255, 257
  - Somatic cell nuclear transfer (SCNT), 430, 433, 435, 440
  - SON, 220, 272–273, 287, 290, 400
  - SOX2, 118, 464–465, 492–493, 498, 503
  - SOX9, 415–417
  - SP1, 114
  - SP-1, 389
  - Sp100, 399
  - SPAD. *See* Speckle-associated domain
  - Spatial position inference of the nuclear genome (SPIN), 284, 337
  - Speckle-associated domain (SPAD), 284, 336–337
  - SPEN, 473–474, 476
  - Spermatogenesis, genome organization, 437–438
  - SPIN. *See* Spatial position inference of the nuclear genome
  - Spliceosome. *See* RNA splicing
  - SPRITE, 283, 310
  - SRF. *See* MRTF/SRF-mediated transcription
  - SRRM2, 272–273, 287, 290
  - SS1, 375
  - SS2, 375
  - SS4, 375
  - STAT3, 114
  - STELLA, 429, 492
  - Stem cell. *See* Pluripotency
  - SUN1, 6, 17, 60, 72–73
  - SUN2, 6, 60, 73
  - SUZ12, 433
  - SV40, 389
  - SWR1, 157–158, 162
- T**
- TADs. *See* Topologically associating domains
  - TAF15, 114, 121
  - TAL1, 378
  - TAZ, 158
  - TBP, 235, 352
  - TCR, 161–162, 378
  - TDP. *See* Timing decision point
  - TDP-43, 460, 469, 475
  - TEAD, 158

## Index

- TERB1, 72
- TERB2, 72
- TERT, 378
- TEs. *See* Transposable elements
- TET, 429
- TET hydroxylases, 371, 374
- TET3, 492
- TFAP2A, 418
- TFIIA, 352–353
- TFIID, 352, 355
- Timing decision point (TDP), 332–333, 336
- Timing transition region (TTR), 328, 330, 335
- TM7SF2, 67
- TNPO1, 392
- Top1, 55
- TOP2B, 381
- Topologically associating domains (TADs)
  - actin mediation, 164
  - cancer studies, 380–381
  - chromatin folding and gene expression in
    - development, 410, 412–416
  - chromatin subcompartments, 110, 124
  - ensemble topologically associating domains, 135, 138–139, 142–143, 145, 147
  - epigenetic reprogramming in early development
    - DNA methylation, 429–430
    - histone modification
      - bivalent modifications, 433
      - H2K119ub, 434
      - H3K27me3, 431–433
      - H3K36me2/3, 434–435
      - H3K4me3, 430–431
      - H3K9me3, 435–436
    - overview, 427–429
    - preimplantation embryo chromatin maturation, 440
    - prospects for study, 440–445
    - transposable elements, 436
  - fertilization, 438
  - formation, 305
  - insulators, 305
  - loop extrusion, 193–194, 198
  - pluripotent cells, 501
  - replication domain relationship, 333, 335
  - stochastic genomic structure, 134–135, 138–139, 142–143, 147
  - three-dimensional modeling of genome folding, 214–215
  - Xist* regulation, 464
- Torsin, 79–80, 373
- TPR, 275
- Transcription. *See also* RNA polymerase II
  - cotranscriptional loading of factors, 358–359
  - elongation and end processing dynamics, 357–358
  - initiation
    - dynamics, 353
    - overview, 352–353
    - posttranslational modifications and histone eviction, 355
  - poly(A) tail isoforms, 358
  - RNA imaging
    - prospects, 360–362
    - techniques, 350–352
  - stability dynamics at promoter, 353, 355
- Transcription factor dynamics
  - brief interaction with chromatin
    - residence times, 233–234
    - search dynamics, 231–233
    - transcription burst, 236–237
  - cancer mutations, 372–373
  - clustering
    - functions in transcription, 241–242
    - mechanisms without phase separation, 241
    - overview, 240–241
    - RNA polymerase II, 241
  - intrinsically disordered regions
    - evolution, 240
    - overview, 237–238
    - phase separation driving, 238–239
    - sequence determination of transcription factor interactions, 239–240
    - stoichiometric complexes, 238
    - target search facilitation, 239
  - overview, 229–230
  - prospects for study, 242
  - techniques for study
    - binding specificity
      - in vitro, 230
      - in vivo, 230
    - live-cell kinetics, 230–231
- Transcription factory, 277
- Transposable elements (TEs)
  - chromatin folding and gene expression in
    - development, 419–420
  - epigenetic reprogramming in early development, 436
- TREX, 400
- TREX1, 101
- TREX2, 50
- Trichostatin A (TSA), 180
- TRIM28, 397, 436
- TRIM33, 397
- TSA. *See* Trichostatin A
- TTR. *See* Timing transition region

- U**  
U2, 274  
U7, 257  
UBE1, 115  
UHRF1, 429, 492  
UNC-84, 73
- V**  
Virus infection. *See also specific viruses*  
cell genome interactions, 393–396  
genome diversity, 389–390  
nuclear compartment interactions  
nuclear speckles, 400–401  
promyelocytic leukemia body, 397–400  
nuclear entry, 390–393  
retrovirus interactions with chromatin and transcription, 396–397
- W**  
WAPL, 135, 201–202  
WASH, 159  
WASP, 164  
WAVE1, 159  
WTAP, 471
- X**  
X chromosome inactivation (XCI)  
chromatin changes, 470  
early development, 458–460  
gene silencing  
kinetics and escape, 465–466  
mechanisms  
overview, 470–471  
polycomb recruitment, 471, 473  
RNA methyltransferase recruitment, 471  
SPEN role, 473–474  
inactive X chromosome  
nuclear localization, 466–467  
structural organization, 469–470  
maintenance, 474–476  
noncoding RNA role, 253, 258  
overview, 457–458  
prospects for study, 476–477  
reconstitution in vitro, 460  
XIST mediation  
expression regulation  
*cis*-regulators, 462–464  
imprinted expression in early mouse  
embryogenesis, 465  
*trans*-regulators, 464–465  
history of study, 460–462  
modules, 462  
RNA compartment, 467–469  
XCI. *See* X chromosome inactivation  
XIST  
expression regulation  
*cis*-regulators, 462–464  
imprinted expression in early mouse  
embryogenesis, 465  
*trans*-regulators, 464–465  
history of study, 460–462  
modules, 462  
RNA compartment, 467–469  
*Xist*, 253, 258, 460, 462–465, 467–477  
XSR, 465
- Y**  
YAP, 95–97, 158  
YEATS, 374  
YTHDC1, 471  
YY1, 465–466
- Z**  
ZBTB7B, 14  
ZFP57, 492  
ZFP809, 397  
ZNF410, 229  
ZRS, 145  
ZSCAN4, 436